2,5-Dimethoxy-4-methylphenylcyclopropylamine
Names
Preferred IUPAC name
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropan-1-amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C12H17NO2/c1-7-4-12(15-3)9(6-11(7)14-2)8-5-10(8)13/h4,6,8,10H,5,13H2,1-3H3 checkY
    Key: HYVPPECPQRBJEQ-UHFFFAOYSA-N checkY
  • InChI=1/C12H17NO2/c1-7-4-12(15-3)9(6-11(7)14-2)8-5-10(8)13/h4,6,8,10H,5,13H2,1-3H3
    Key: HYVPPECPQRBJEQ-UHFFFAOYAN
  • O(c1c(cc(OC)c(c1)C2CC2N)C)C
Properties
C12H17NO2
Molar mass 207.273 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

2,5-Dimethoxy-4-methylphenylcyclopropylamine (DMCPA) is a lesser-known psychedelic drug and a substituted amphetamine. DMCPA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 15–20 mg and the duration is listed as 4–8 hours.[1] DMCPA produces open-eye visuals, anorexia, and psychedelic dreams. Shulgin gives it a +++ on the Shulgin Rating Scale.

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

Pharmacology

Very little data exists about the pharmacological properties, metabolism, and toxicity of DMCPA.

See also

References

  1. ^ DMCPA Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
Categories